US320A
(en)
|
|
1837-07-31 |
|
John dainty |
US5985A
(en)
|
|
1848-12-26 |
|
Pianoforte-action |
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
US3862925A
(en)
|
1973-07-05 |
1975-01-28 |
American Home Prod |
Preparation of somatotropin release inhibiting factor and intermediates therefor
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
US3842067A
(en)
|
1973-07-27 |
1974-10-15 |
American Home Prod |
Synthesis of(des-asn5)-srif and intermediates
|
JPS5726506B2
(es)
|
1974-03-08 |
1982-06-04 |
|
|
US4105603A
(en)
|
1977-03-28 |
1978-08-08 |
The Salk Institute For Biological Studies |
Peptides which effect release of hormones
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4752601A
(en)
|
1983-08-12 |
1988-06-21 |
Immunetech Pharmaceuticals |
Method of blocking immune complex binding to immunoglobulin FC receptors
|
US6054561A
(en)
|
1984-02-08 |
2000-04-25 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
US5185432A
(en)
|
1986-02-26 |
1993-02-09 |
Oncogen |
Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US5985599A
(en)
|
1986-05-29 |
1999-11-16 |
The Austin Research Institute |
FC receptor for immunoglobulin
|
US4954617A
(en)
|
1986-07-07 |
1990-09-04 |
Trustees Of Dartmouth College |
Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
JP3095168B2
(ja)
|
1988-02-05 |
2000-10-03 |
エル. モリソン,シェリー |
ドメイン‐変性不変部を有する抗体
|
FR2626882B1
(fr)
|
1988-02-08 |
1991-11-08 |
Ire Celltarg Sa |
Conjugues de derives de vinca comportant une chaine detergente en position c-3
|
US4861579A
(en)
|
1988-03-17 |
1989-08-29 |
American Cyanamid Company |
Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
|
EP0449828A1
(en)
|
1988-05-27 |
1991-10-09 |
Schering Biotech Corporation |
HUMAN Fc$g(g) RECEPTOR III
|
US5169933A
(en)
|
1988-08-15 |
1992-12-08 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
US5576184A
(en)
|
1988-09-06 |
1996-11-19 |
Xoma Corporation |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens
|
DE68928427T2
(de)
|
1988-09-15 |
1998-06-04 |
Univ Columbia |
Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
CA2018248A1
(en)
|
1989-06-07 |
1990-12-07 |
Clyde W. Shearman |
Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
|
GB8916400D0
(en)
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
GB9017024D0
(en)
|
1990-08-03 |
1990-09-19 |
Erba Carlo Spa |
New linker for bioactive agents
|
US5364930A
(en)
|
1990-10-16 |
1994-11-15 |
Northwestern University |
Synthetic C1q peptide fragments
|
GB9105245D0
(en)
|
1991-03-12 |
1991-04-24 |
Lynxvale Ltd |
Binding molecules
|
ES2181673T3
(es)
|
1991-05-01 |
2003-03-01 |
Jackson H M Found Military Med |
Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
GB9112536D0
(en)
|
1991-06-11 |
1991-07-31 |
Celltech Ltd |
Chemical compounds
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
US5223408A
(en)
|
1991-07-11 |
1993-06-29 |
Genentech, Inc. |
Method for making variant secreted proteins with altered properties
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
AU2605592A
(en)
|
1991-10-15 |
1993-04-22 |
Atrix Laboratories, Inc. |
Polymeric compositions useful as controlled release implants
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
EP0682710B1
(en)
|
1993-02-10 |
2003-10-29 |
Unilever Plc |
Isolation process using immobilized proteins with specific binding capacities
|
US5877396A
(en)
|
1993-04-23 |
1999-03-02 |
Sloan Kettering Institute For Cancer Research |
Mice mutant for functional Fc receptors and method of treating autoimmune diseases
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
EP0714409A1
(en)
|
1993-06-16 |
1996-06-05 |
Celltech Therapeutics Limited |
Antibodies
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
EP0711303B2
(en)
|
1993-07-30 |
2009-06-10 |
Affymax, Inc. |
Biotinylation of proteins
|
GB9316989D0
(en)
|
1993-08-16 |
1993-09-29 |
Lynxvale Ltd |
Binding molecules
|
DK0730470T3
(da)
|
1993-11-10 |
2002-06-03 |
Enzon Inc |
Forbedrede interferonpolymerkonjugater
|
US5532159A
(en)
|
1994-04-01 |
1996-07-02 |
The Ohio State University |
Monoclonal antibody to canine placental oncofetal protein for detecting cancer
|
US7473423B2
(en)
|
1994-04-29 |
2009-01-06 |
Mayo Foundation For Medical Education And Research |
Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US6132764A
(en)
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
US5736152A
(en)
|
1995-10-27 |
1998-04-07 |
Atrix Laboratories, Inc. |
Non-polymeric sustained release delivery system
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
JP2000506165A
(ja)
|
1996-03-04 |
2000-05-23 |
ザ ペン ステイト リサーチ ファウンデーション |
細胞インターナリゼーションを増強するための物質および方法
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6699658B1
(en)
|
1996-05-31 |
2004-03-02 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
US6300065B1
(en)
|
1996-05-31 |
2001-10-09 |
Board Of Trustees Of The University Of Illinois |
Yeast cell surface display of proteins and uses thereof
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
US6025485A
(en)
|
1997-02-14 |
2000-02-15 |
Arcaris, Inc. |
Methods and compositions for peptide libraries displayed on light-emitting scaffolds
|
US6339069B1
(en)
|
1996-10-15 |
2002-01-15 |
Elan Pharmaceuticalstechnologies, Inc. |
Peptide-lipid conjugates, liposomes and lipsomal drug delivery
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
PT954282E
(pt)
|
1997-01-16 |
2005-06-30 |
Massachusetts Inst Technology |
Preparacao de particulas para inalacao
|
JP2001512438A
(ja)
|
1997-02-11 |
2001-08-21 |
イムノメディクス,インコーポレイテッド |
αガラクトシルエピトープで標識された抗体による免疫応答の刺激
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
DE19721700C1
(de)
|
1997-05-23 |
1998-11-19 |
Deutsches Krebsforsch |
Mutierter OKT3-Antikörper
|
WO1999019362A1
(en)
|
1997-10-15 |
1999-04-22 |
Medarex, Inc. |
BISPECIFIC MOLECULES DIRECTED TO TUMOR ASSOCIATED GLYCOPROTEIN-72 AND Fc RECEPTOR
|
CA2248971A1
(en)
|
1997-10-31 |
1999-04-30 |
Kyowa Hakko Kogyo Co., Ltd. |
.beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use
|
EA200000848A1
(ru)
|
1998-02-17 |
2001-04-23 |
Медарекс, Инк. |
Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
|
BR9908226A
(pt)
|
1998-02-25 |
2000-10-24 |
Lexigen Pharm Corp |
Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
|
ES2312205T3
(es)
|
1998-03-10 |
2009-02-16 |
Genentech, Inc. |
Nuevo polipeptido y acidos nucleicos que lo codifican.
|
US6455263B2
(en)
|
1998-03-24 |
2002-09-24 |
Rigel Pharmaceuticals, Inc. |
Small molecule library screening using FACS
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
DK1068241T3
(da)
|
1998-04-02 |
2008-02-04 |
Genentech Inc |
Antistofvarianter og fragmenter deraf
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
EP0953639A1
(en)
|
1998-04-30 |
1999-11-03 |
Boehringer Ingelheim International GmbH |
FAPalpha-specific antibody with improved producibility
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
ES2198922T3
(es)
|
1998-06-24 |
2004-02-01 |
Advanced Inhalation Research, Inc. |
Particulas porosas grandes emitadas por un inhalador.
|
US6696550B2
(en)
|
1998-07-23 |
2004-02-24 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-CCR2 antibodies and methods of use therefor
|
CA2341029A1
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
US7315786B2
(en)
|
1998-10-16 |
2008-01-01 |
Xencor |
Protein design automation for protein libraries
|
JP2002530066A
(ja)
|
1998-11-19 |
2002-09-17 |
スミスクライン・ビーチャム・コーポレイション |
Rhammアンタゴニスト抗体
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
US20030190669A1
(en)
|
1998-12-30 |
2003-10-09 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
CA2362592A1
(en)
|
1999-02-12 |
2000-08-17 |
Genetics Institute, Inc. |
Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
WO2000068266A1
(en)
|
1999-05-11 |
2000-11-16 |
Eli Lilly And Company |
Amyloid precursor protein protease and related nucleic acid compounds
|
EP1514933A1
(en)
|
1999-07-08 |
2005-03-16 |
Research Association for Biotechnology |
Secretory protein or membrane protein
|
US6429303B1
(en)
|
1999-09-03 |
2002-08-06 |
Curagen Corporation |
Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
|
CA2389916A1
(en)
|
1999-09-03 |
2001-03-15 |
Human Genome Sciences, Inc. |
B7-like polynucleotides, polypeptides, and antibodies
|
US6406840B1
(en)
|
1999-12-17 |
2002-06-18 |
Biomosaic Systems, Inc. |
Cell arrays and the uses thereof
|
US6541225B1
(en)
|
2000-01-26 |
2003-04-01 |
Raven Biotechnologies, Inc. |
Methods and compositions for generating human monoclonal antibodies
|
EP1252192B1
(en)
|
2000-02-11 |
2006-08-16 |
MERCK PATENT GmbH |
Enhancing the circulating half-life of antibody-based fusion proteins
|
WO2001071005A2
(en)
|
2000-03-24 |
2001-09-27 |
Micromet Ag |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
AU5345901A
(en)
|
2000-04-13 |
2001-10-30 |
Univ Rockefeller |
Enhancement of antibody-mediated immune responses
|
US20060154313A1
(en)
|
2000-04-13 |
2006-07-13 |
Immunex Corporation |
Human B7 polypeptide B7-H3A
|
DE60132699T2
(de)
|
2000-06-06 |
2009-01-29 |
Bristol-Myers Squibb Co. |
Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
|
EP1892251A3
(en)
|
2000-06-06 |
2008-12-31 |
Brystol-Myers Squibb Company |
B7-related nucleic acids and polypeptides and their uses for immunomodulation
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP1294904A1
(en)
|
2000-06-30 |
2003-03-26 |
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. |
Heterodimeric fusion proteins
|
WO2002010187A1
(en)
|
2000-07-27 |
2002-02-07 |
Mayo Foundation For Medical Education And Research |
B7-h3 and b7-h4, novel immunoregulatory molecules
|
WO2002022683A1
(fr)
|
2000-09-12 |
2002-03-21 |
Kirin Beer Kabushiki Kaisha |
Nouvelle membrane a paroi cellulaire dendritique et son utilisation
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
EP1399187A4
(en)
|
2000-10-18 |
2005-09-21 |
Sloan Kettering Inst Cancer |
APPLICATIONS OF MONOCLONAL ANTIBODY 8H9
|
US7737258B2
(en)
|
2000-10-18 |
2010-06-15 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
WO2002086070A2
(en)
|
2001-04-18 |
2002-10-31 |
Dyax Corp. |
Binding molecules for fc-region polypeptides
|
DE60230736D1
(de)
|
2001-04-30 |
2009-02-26 |
Lilly Co Eli |
HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
DE60124912T2
(de)
|
2001-09-14 |
2007-06-14 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, Tandem-Fv-Antikörper
|
US20030077282A1
(en)
|
2001-10-12 |
2003-04-24 |
Bigler Michael Eric |
Use of bispecific antibodies to regulate immune responses
|
EP1443961B1
(en)
|
2001-10-25 |
2009-05-06 |
Genentech, Inc. |
Glycoprotein compositions
|
US7261890B2
(en)
|
2001-12-21 |
2007-08-28 |
Idexx Laboratories, Inc. |
Methods for using canine immunoglobulin variable domains and caninized antibodies
|
WO2003066095A2
(en)
|
2002-02-07 |
2003-08-14 |
Vereniging Voor Christelijk Wetenschappelijk Onderwijs |
MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
WO2003074679A2
(en)
|
2002-03-01 |
2003-09-12 |
Xencor |
Antibody optimization
|
EP1354600A1
(en)
|
2002-04-19 |
2003-10-22 |
Affimed Therapeutics AG |
Antibody combination useful for tumor therapy
|
CA2485373A1
(en)
|
2002-05-10 |
2003-11-20 |
Medimmune, Inc. |
Epha2 monoclonal antibodies and methods of use thereof
|
DE60334453D1
(de)
|
2002-05-30 |
2010-11-18 |
Macrogenics Inc |
Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
|
PT1565489E
(pt)
|
2002-06-19 |
2011-02-23 |
Raven Biotechnologies Inc |
Anticorpos internalizantes específicos para o alvo de superfície celular raag10
|
EP1521769B1
(de)
|
2002-07-09 |
2015-09-09 |
Dömling, Alexander |
Tubulysinkonjugate
|
CA2494310A1
(en)
|
2002-08-01 |
2004-02-12 |
Immunomedics, Inc. |
Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US20090017023A1
(en)
|
2002-08-14 |
2009-01-15 |
Macrogenics, Inc. |
FcGammaRIIB Specific Antibodies and Methods of Use Thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
DK2345671T3
(en)
|
2002-09-27 |
2016-02-15 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
AU2003288467A1
(en)
|
2002-12-13 |
2004-07-09 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP1596804A4
(en)
|
2003-01-13 |
2008-02-06 |
Macrogenics Inc |
SOLUBLE FCyR FUSION PROTEINS AND METHODS OF USE
|
DE10303664A1
(de)
|
2003-01-23 |
2004-08-12 |
Nemod Immuntherapie Ag |
Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
WO2004080979A1
(en)
|
2003-03-14 |
2004-09-23 |
Lg Life Sciences Ltd. |
Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
|
US20050002935A1
(en)
|
2003-04-17 |
2005-01-06 |
Vincent Ling |
Use of B7-H3 as an immunoregulatory agent
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
AU2003265522A1
(en)
|
2003-08-18 |
2005-03-10 |
Macrogenics, Inc. |
FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
BRPI0414513A
(pt)
|
2003-09-18 |
2007-01-02 |
Raven Biotechnologies Inc |
kid3 e anticorpos de kid3 que se ligam a ele
|
AU2004284075A1
(en)
|
2003-10-22 |
2005-05-06 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
|
BR122018071968B8
(pt)
|
2003-11-06 |
2021-07-27 |
Seattle Genetics Inc |
conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
US20080089892A1
(en)
|
2004-01-12 |
2008-04-17 |
Eli Lilly And Co. |
Fc Region Variants
|
DE602005027309D1
(de)
|
2004-01-16 |
2011-05-19 |
Regeneron Pharma |
Zur aktivierung von rezeptoren fähige fusionspolypeptide
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
AU2005219626B2
(en)
|
2004-03-01 |
2010-11-18 |
Medimmune Limited |
11-hydroxy-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of C2 substituted pyrrolobenzodiazepines
|
CA2563379A1
(en)
|
2004-03-31 |
2005-10-20 |
Centocor, Inc. |
Human glp-1 mimetibodies, compositions, methods and uses
|
KR20070038453A
(ko)
|
2004-04-16 |
2007-04-10 |
마크로제닉스, 인크. |
FcγRIIB-특이적 항체 및 그의 사용 방법
|
KR101297146B1
(ko)
|
2004-05-10 |
2013-08-21 |
마크로제닉스, 인크. |
인간화 FcγRIIB 특이적 항체 및 그의 사용 방법
|
GB0410725D0
(en)
|
2004-05-13 |
2004-06-16 |
Spirogen Ltd |
Pyrrolobenzodiazepine therapeutic agents
|
BRPI0511782B8
(pt)
|
2004-06-03 |
2021-05-25 |
Novimmune Sa |
anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
|
EP1765868B1
(en)
|
2004-06-07 |
2016-04-20 |
MacroGenics, Inc. |
Transferrin receptor antibodies
|
WO2006009901A2
(en)
|
2004-06-18 |
2006-01-26 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
US7560111B2
(en)
|
2004-07-22 |
2009-07-14 |
Genentech, Inc. |
HER2 antibody composition
|
EP1773884B1
(en)
|
2004-08-03 |
2012-03-07 |
Innate Pharma |
Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
|
DK1776384T3
(da)
|
2004-08-04 |
2013-09-02 |
Mentrik Biotech Llc |
VARIANT-Fc-REGIONER
|
CN101052653A
(zh)
|
2004-09-02 |
2007-10-10 |
健泰科生物技术公司 |
抗FcγRⅡB受体抗体及其用途
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
EP1833849A4
(en)
|
2004-12-15 |
2009-08-05 |
Macrogenics Inc |
FC-GAMMA-RIIB-SPECIFIC ANTIBODIES AND METHODS FOR THEIR USE
|
US7687242B2
(en)
|
2005-01-12 |
2010-03-30 |
Raven Biotechnologies, Inc. |
KID31 and antibodies that bind thereto
|
US7847070B2
(en)
|
2005-01-31 |
2010-12-07 |
Raven Biotechnologies, Inc. |
LUCA2 and antibodies that bind thereto
|
MX2007009222A
(es)
|
2005-02-02 |
2008-01-16 |
Raven Biotechnologies Inc |
Moduladores de adam-9.
|
US7572896B2
(en)
|
2005-02-03 |
2009-08-11 |
Raven Biotechnologies, Inc. |
Antibodies to oncostatin M receptor
|
CN104059150B
(zh)
|
2005-02-04 |
2018-10-02 |
宏观基因有限公司 |
结合epha2的抗体及其使用方法
|
US20060193849A1
(en)
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
AU2006232310B9
(en)
|
2005-04-06 |
2011-07-21 |
Ibc Pharmaceuticals, Inc. |
Improved stably tethered structures of defined compositions with multiple functions or binding specificities
|
EP1874824A4
(en)
|
2005-04-06 |
2009-12-30 |
Ibc Pharmaceuticals Inc |
METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
|
WO2006110593A2
(en)
|
2005-04-07 |
2006-10-19 |
Macrogenics, Inc. |
Biological targets for the diagnosis, treatment and prevention of cancer
|
CA2605024C
(en)
|
2005-04-15 |
2018-05-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US8101183B2
(en)
|
2005-05-06 |
2012-01-24 |
Zymogentics, Inc. |
Variable region sequences of IL-31 monoclonal antibodies
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
SG10201504917PA
(en)
|
2005-07-11 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
CN101627054A
(zh)
|
2005-07-11 |
2010-01-13 |
马克罗基因公司 |
用人源化抗cd16a抗体治疗自身免疫疾病的方法
|
DK1919503T3
(en)
|
2005-08-10 |
2014-12-15 |
Macrogenics Inc |
Identification and preparation of antibodies with variant fc regions and methods of use thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
AU2006283532B2
(en)
|
2005-08-19 |
2012-04-26 |
Abbvie Inc. |
Dual variable domain immunoglobin and uses thereof
|
DE602006006199D1
(de)
|
2005-10-05 |
2009-05-20 |
Spirogen Ltd |
4-ä4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo ä2, 1-cüä1,4übenzodiazepin-8-yloxy)-butyrylaminoü-1h-pyrrol-2-carbonsäurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
|
EP1937851A4
(en)
|
2005-10-19 |
2010-08-25 |
Ibc Pharmaceuticals Inc |
METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE
|
WO2007055916A2
(en)
|
2005-11-07 |
2007-05-18 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
CA2633486C
(en)
|
2005-12-16 |
2015-02-03 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
FR2894982A1
(fr)
|
2005-12-16 |
2007-06-22 |
Lab Francais Du Fractionnement |
Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
|
AU2007226752A1
(en)
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
EP1999154B1
(en)
|
2006-03-24 |
2012-10-24 |
Merck Patent GmbH |
Engineered heterodimeric protein domains
|
WO2007117600A2
(en)
|
2006-04-07 |
2007-10-18 |
Macrogenics, Inc. |
Combination therapy for treating autoimmune diseases
|
EP2021029B1
(en)
|
2006-05-26 |
2014-06-11 |
MacroGenics, Inc. |
Humanized fc gamma riib-specific antibodies and methods of use thereof
|
MX363905B
(es)
|
2006-06-12 |
2019-04-08 |
Aptevo Res & Development Llc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
EP2037961B1
(en)
|
2006-06-14 |
2015-11-11 |
MacroGenics, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
EP2029173B1
(en)
|
2006-06-26 |
2016-07-20 |
MacroGenics, Inc. |
Fc riib-specific antibodies and methods of use thereof
|
JP5829004B2
(ja)
|
2006-06-30 |
2015-12-09 |
ノボ・ノルデイスク・エー/エス |
抗nkg2a抗体とその使用
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
US10118970B2
(en)
|
2006-08-30 |
2018-11-06 |
Genentech, Inc. |
Multispecific antibodies
|
US20080112961A1
(en)
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
CA2668800A1
(en)
|
2006-11-08 |
2008-06-05 |
Macrogenics West, Inc. |
Tes7 and antibodies that bind thereto
|
US7992748B2
(en)
|
2006-11-17 |
2011-08-09 |
North Safety Products, Inc. |
Earplug dispenser
|
PL2099823T5
(pl)
|
2006-12-01 |
2023-02-20 |
Seagen Inc. |
Wariant środków wiążących cel i jego zastosowania
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
CA2672049C
(en)
|
2006-12-08 |
2016-05-10 |
Lexicon Pharmaceuticals, Inc. |
Monoclonal antibodies against angptl3
|
EP2094302A4
(en)
|
2006-12-21 |
2010-12-08 |
Macrogenics Inc |
METHODS FOR THE TREATMENT OF LADA-LIKE DIABETES AND OTHER AUTOIMMUNE DIABETES OF THE ADULT USING IMMUNOSUPPRESSANT MONOCLONAL ANTIBODIES HAVING REDUCED TOXICITY
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
AU2008207945A1
(en)
|
2007-01-22 |
2008-07-31 |
Macrogenics West, Inc. |
Human cancer stem cells
|
EP2121008A4
(en)
|
2007-03-22 |
2010-03-31 |
Sloan Kettering Inst Cancer |
USES OF MONOCLONAL ANTIBODY 8H9
|
CA2682626A1
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
FR2916763B1
(fr)
|
2007-05-31 |
2013-11-15 |
Biomerieux Sa |
Nouveaux substrats de peptidase
|
WO2009151717A2
(en)
|
2008-04-02 |
2009-12-17 |
Macrogenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
JP5718637B2
(ja)
|
2007-06-21 |
2015-05-13 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
EP2224958A2
(en)
|
2007-11-30 |
2010-09-08 |
Bristol-Myers Squibb Company |
Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
|
US8802089B2
(en)
|
2008-01-03 |
2014-08-12 |
Genmab A/S |
Monoclonal antibodies against CD32B
|
CA2720368C
(en)
|
2008-04-02 |
2017-08-22 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
US20090262732A1
(en)
|
2008-04-16 |
2009-10-22 |
Barry Wood |
Data Communications Network
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
ES2675730T3
(es)
|
2008-06-04 |
2018-07-12 |
Macrogenics, Inc. |
Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
|
CA2735193A1
(en)
|
2008-08-26 |
2010-03-11 |
Macrogenics, Inc. |
T-cell receptor antibodies and methods of use thereof
|
WO2010028797A1
(en)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Multivalent antibodies
|
WO2010028795A1
(en)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Multivalent antibodies
|
WO2010028796A1
(en)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Trispecific hexavalent antibodies
|
MX2011004625A
(es)
|
2008-11-03 |
2011-07-20 |
Syntarga Bv |
Analogos cc-1065 novedosos y sus conjugados.
|
CN106432503B
(zh)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
共价双抗体及其用途
|
PT3903829T
(pt)
|
2009-02-13 |
2023-06-02 |
Immunomedics Inc |
Imunoconjugados com uma ligação intracelular clivável
|
ES2572728T3
(es)
|
2009-03-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HER biespecíficos
|
RU2570633C2
(ru)
|
2009-05-27 |
2015-12-10 |
Ф.Хоффманн-Ля Рош Аг |
Три- или тетраспецифические антитела
|
US8277919B2
(en)
|
2009-07-23 |
2012-10-02 |
VMO Systems, Inc. |
Reflective coating for an optical disc
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
ES2582001T3
(es)
|
2010-02-25 |
2016-09-08 |
Affimed Gmbh |
Molécula que se une a antígeno y usos de la misma
|
US20110206672A1
(en)
|
2010-02-25 |
2011-08-25 |
Melvyn Little |
Antigen-Binding Molecule And Uses Thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
CA2791658C
(en)
|
2010-03-04 |
2019-10-01 |
Macrogenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
PL2560645T3
(pl)
|
2010-04-21 |
2017-01-31 |
Syntarga B.V. |
Koniugaty analogów CC-1065 i łączników dwufunkcyjnych
|
RU2624027C2
(ru)
|
2010-04-23 |
2017-06-30 |
Дженентек, Инк. |
Получение гетеромультимерных белков
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
WO2012009544A2
(en)
|
2010-07-14 |
2012-01-19 |
Amgen Inc. |
Domain insertion immunoglobulin
|
JP5964300B2
(ja)
|
2010-08-02 |
2016-08-03 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
EP2600866A4
(en)
|
2010-08-06 |
2013-12-11 |
Endocyte Inc |
PROCESS FOR THE PRODUCTION OF TUBULYSINES
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
SG191977A1
(en)
*
|
2011-02-01 |
2013-08-30 |
Genmab As |
Human antibodies and antibody-drug conjugates against cd74
|
RS57279B1
(sr)
|
2011-04-25 |
2018-08-31 |
Daiichi Sankyo Co Ltd |
Anti-b7-h3 antitelo
|
ES2703780T3
(es)
|
2011-05-17 |
2019-03-12 |
Trion Res Gmbh |
Preparación de una vacuna que contiene anticuerpos trifuncionales con propiedades potenciadoras de la inmunogenicidad del antígeno
|
JP6145088B2
(ja)
|
2011-05-21 |
2017-06-07 |
マクロジェニクス,インコーポレーテッド |
脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
|
UA117072C2
(uk)
|
2011-05-21 |
2018-06-11 |
Макродженікс, Інк. |
Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
|
WO2012162583A1
(en)
|
2011-05-26 |
2012-11-29 |
Ibc Pharmaceuticals, Inc. |
Design and construction of novel multivalent antibodies
|
US20150045540A1
(en)
|
2011-06-28 |
2015-02-12 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
US20140155581A1
(en)
|
2011-07-06 |
2014-06-05 |
Medimmune, Llc |
Methods For Making Multimeric Polypeptides
|
WO2013006867A1
(en)
|
2011-07-07 |
2013-01-10 |
Massachussetts Institute Of Technology |
Methods and apparatus for ultrathin catalyst layer for photoelectrode
|
JP5938473B2
(ja)
|
2011-07-22 |
2016-06-22 |
アフィメート テラポイティクス アーゲー |
多価抗原結合Fv分子
|
JP2014533249A
(ja)
|
2011-11-07 |
2014-12-11 |
メディミューン,エルエルシー |
多重特異性を持つ多価結合タンパク質およびその使用
|
AU2013216943B2
(en)
|
2012-02-10 |
2018-04-19 |
Research Corporation Technologies, Inc. |
Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
|
WO2013163427A1
(en)
|
2012-04-25 |
2013-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibodies to treat hiv-1 infection
|
CA2869529A1
(en)
|
2012-05-24 |
2013-11-28 |
Raffaella CASTOLDI |
Multispecific antibodies
|
AU2013285355A1
(en)
|
2012-07-06 |
2015-01-29 |
Genmab B.V. |
Dimeric protein with triple mutations
|
WO2014022540A1
(en)
|
2012-08-02 |
2014-02-06 |
Regeneron Pharmaceuticals, Inc. |
Multivalent antigen-binding proteins
|
EP3632471A1
(en)
|
2012-10-11 |
2020-04-08 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate
|
PT2906296T
(pt)
|
2012-10-12 |
2018-06-01 |
Medimmune Ltd |
Conjugados de pirrolobenzodiazepina-anticorpo
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
US9562099B2
(en)
*
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
EP3892294A1
(en)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Site-specific antibody conjugation methods and compositions
|
SG10201911860VA
(en)
*
|
2014-01-10 |
2020-02-27 |
Synthon Biopharmaceuticals Bv |
Duocarmycin adcs showing improved in vivo antitumor activity
|
MY177390A
(en)
|
2014-01-10 |
2020-09-14 |
Byondis Bv |
Method for purifying cys-linked antibody-drug conjugates
|
CN106604740A
(zh)
|
2014-02-14 |
2017-04-26 |
宏观基因有限公司 |
用于治疗血管化癌症的改进的方法
|
KR20160142392A
(ko)
|
2014-04-11 |
2016-12-12 |
메디뮨 엘엘씨 |
튜부리신 유도체
|
EP3148580B1
(en)
|
2014-05-29 |
2021-01-20 |
MacroGenics, Inc. |
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
|
CN106458892B
(zh)
|
2014-06-05 |
2019-10-18 |
斯索恩生物制药有限公司 |
用于制备倍癌霉素前药的改进方法
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
WO2016044383A1
(en)
|
2014-09-17 |
2016-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 antibodies (b7h3)
|
CN108026123B
(zh)
|
2015-06-15 |
2021-02-05 |
杭州多禧生物科技有限公司 |
用于偶联的亲水链接体
|
AU2015242213A1
(en)
|
2015-07-12 |
2018-03-08 |
Hangzhou Dac Biotech Co., Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US10292961B2
(en)
|
2015-07-15 |
2019-05-21 |
Hangzhou Dac Biotech Co., Ltd. |
Disulfur bridge linkers for conjugation of a cell-binding molecule
|
WO2017062615A2
(en)
|
2015-10-08 |
2017-04-13 |
Macrogenics, Inc. |
Combination therapy for the treatment of cancer
|
RU2731202C2
(ru)
|
2015-10-08 |
2020-08-31 |
Макродженикс, Инк. |
Комбинированная терапия для лечения рака
|
WO2017114550A1
(en)
|
2015-12-28 |
2017-07-06 |
Telecom Italia S.P.A. |
Method for managing the reputation of members of an online community
|
SG11201808979UA
(en)
|
2016-04-15 |
2018-11-29 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
AU2018224094A1
(en)
|
2017-02-24 |
2019-09-19 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|